1. Search Result
Search Result
Results for "

heavy chain

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

6

Peptides

13

Inhibitory Antibodies

4

Natural
Products

17

Recombinant Proteins

18

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P99325

    IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

    TNF Receptor Inflammation/Immunology
    Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
  • HY-P990360

    Inhibitory Antibodies Inflammation/Immunology
    Anti-CD9 Antibody is a CHO expressed human antibody targeting CD9. Anti-CD9 Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990244

    Inhibitory Antibodies Others
    Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is a mouse-derived IgG1 type antibody inhibitor, targeting to rat FcRn heavy chain heterodimers.
  • HY-P990818

    Inhibitory Antibodies Others
    Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is a kind of mouse IgG1 in vivo mouse antibody, targeting to FcRn heavy chain heterodimers. The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P990695

    Inhibitory Antibodies Inflammation/Immunology
    Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
  • HY-P990757

    TNF Receptor PD-1/PD-L1 Inflammation/Immunology
    Ragistomig is an anti-TNFRSF9/CD274 IgG1 monoclonal antibody composed of a κ light chain and a variable region with a λ light chain and an IgG1 heavy chain. The overall structure is a dimer composed of two identical IgG1 heavy chains .
  • HY-P990718

    PD-1/PD-L1 Inflammation/Immunology
    Cemavafusp is an anti-PD-L1 monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
  • HY-P990693

    ALXN-1820

    Inhibitory Antibodies Inflammation/Immunology
    Tarperprumig is an anti-ALB/CFP monoclonal antibody composed of 2 heavy chain variable regions linked together .
  • HY-P990748

    Interleukin Related Inflammation/Immunology
    Lunsekimig is an anti-TSLP/IL13/ALB monoclonal antibody composed of 5 sequentially linked variable region heavy chains .
  • HY-P990088

    VEGFR PD-1/PD-L1 Cardiovascular Disease
    Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .
  • HY-P9954

    CD3 Cancer
    Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
  • HY-P99963

    HS636

    PD-1/PD-L1 Cancer
    Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
  • HY-P99463

    AVB-S6-500

    TAM Receptor Cancer
    Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: